TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07860710: Japan Open-Label Linerixibat Safety and Tolerability Extension Study for Cholestatic Pruritus in PBC

Sponsor: GlaxoSmithKline · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 40 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$15,086,080

Rescue Site Savings

+$9,947,384

Unlock Full NCT07860710 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07860710 Rescue Dossier →